Show simple item record

dc.contributor.authorKirby, Michael
dc.contributor.authorSchnetzler, G.
dc.contributor.authorZou, K.H.
dc.contributor.authorSymonds, T.
dc.date.accessioned2011-08-16T09:01:07Z
dc.date.available2011-08-16T09:01:07Z
dc.date.issued2011
dc.identifier.citationKirby , M , Schnetzler , G , Zou , K H & Symonds , T 2011 , ' Prevalence and detection rate of underlying disease in men with erectile dysfunction receiving phosphodiesterase type 5 inhibitors in the United Kingdom : A retrospective database study ' , International Journal of Clinical Practice , vol. 65 , no. 7 , pp. 797-806 . https://doi.org/10.1111/j.1742-1241.2011.02693.x
dc.identifier.issn1368-5031
dc.identifier.otherPURE: 309950
dc.identifier.otherPURE UUID: b1136dd8-f5e1-4908-826e-46b17e156058
dc.identifier.otherScopus: 79959325737
dc.identifier.urihttp://hdl.handle.net/2299/6243
dc.descriptionThe definitive version can be found at : http://onlinelibrary.wiley.com/ Copyright Wiley-Blackwell [Full text of this article is not available in the UHRA]
dc.description.abstractAim : To determine the rate of newly detected underlying disease in men receiving their first (index) phosphodiesterase type 5 inhibitor (PDE5i) prescription. Methods : This non-interventional, retrospective study used anonymised patient records from UK general practices identified from the THIN database. Records of men aged ≥ 18 years, who received an index PDE5i prescription between January 1999 and June 2008 and with a continuous medical history (≥ 60 months) before the index prescription were included. Primary end-points were the prevalence of underlying disease prior to the index prescription and to establish the detection rate, defined as cumulative incidence of such a diagnosis in the 3 months following the index prescription. Assessments included comparison with age-matched controls, comparison with identical time periods immediately before and 1 year after, index prescription, and changes over time during the study period. Descriptive statistics, analysis of proportions and multivariate logistic regression analysis were used. Results: Among the 24,708 patients receiving a PDE5i, the prevalence of any underlying diagnosis before the index prescription was 70.23%; prevalence of vasculogenic disease was highest (48.20%). The detection rate of any underlying disease was 11.53%, and again highest for vasculogenic disease (4.07%). Compared with an age-matched control population, the additional detection rate of an unknown underlying disease at PDE5i prescription was 45 for hypertension, 61 for hypercholesterolaemia, 38 for diabetes and 5 for hypogonadism per 10,000 men. Conclusion : Only a minority of men with erectile dysfunction have a previously undiagnosed important underlying disease that is uncovered at the time of an initial PDE5i prescription by a GP.en
dc.language.isoeng
dc.relation.ispartofInternational Journal of Clinical Practice
dc.titlePrevalence and detection rate of underlying disease in men with erectile dysfunction receiving phosphodiesterase type 5 inhibitors in the United Kingdom : A retrospective database studyen
dc.contributor.institutionCentre for Postgraduate Medicine
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.contributor.institutionEDS Trial
dc.contributor.institutionPatient Experience and Public Involvement
dc.description.statusPeer reviewed
rioxxterms.versionofrecordhttps://doi.org/10.1111/j.1742-1241.2011.02693.x
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record